August 2025 QQ: Coagulation Control Proteins

Our August 2026 Quick Question is a simple quiz that asks, “Which is NOT an endogenous coag control protein?” This is your opportunity to review the plasma-based coagulation mechanism and recall the functions of the control proteins, available in our Educational Module entitled Coagulation Overview. One of these is NOT an endogenous control protein for […]

Comments (0)

Quick Question Archive

Jul 28 2026

george

July 2026 QQ Summary: VWD Therapeutic

Our July 2026 QQ asked: What VWD therapeutic is NOT a replacement factor? Our 24 participants responded… Desmopressin: 18 (75%) Humate P: 1 (4%) Vonvendi: 4 (17%) Wilate: 1 (4%) VWD bleeding is first managed by applying “PRICE:” protection, rest, ice, compression, and elevation. Next, desmopressin (DDAVP) is administered via injection, infusion, and, in Europe, […]

Comments (0)

Quick Question Archive

Jul 20 2026

george

Emicizumab Therapy for the Newborn

Click for this Hemostasis Today column, Abdul Mannan: HAVEN 7 and the Future of Early Haemophilia Care. For a detailed follow-up to the HAVEN 7 trial, check your medical library for de Kovel M, Kenet G, Motwani J, et al; PedNet Study group. FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs […]

Bleeding Disorders

Risk of PE in Octogenarians

Here is a provocative open-access case-control article: Lipa AJ, Janata-Schwatczek K, Sterz M, et al. Too old for PESI?: risk stratification of octogenarians with pulmonary embolism in the emergency department. Semin Thromb Hemost. 2026. doi: 10.1055/a-2896-8297. PMID: 42361814. Abstract Pulmonary embolism (PE) in octogenarians (i.e., patients >80 years) is associated with substantial morbidity and mortality, yet […]

Thrombophilia

Review: Laboratory Monitoring and Measuring of Clinical Anticoagulants

Check your medical library for this July, 2026 review: Favaloro EJ, Reardon B, Pasalic L. Laboratory monitoring and measuring of clinical anticoagulants. Semin Thromb Hemost. 2026. doi: 10.1055/a-2907-8841. PMID: 42442704. Abstract Haemostasis reflects a balance between procoagulant and anticoagulant forces. A relative excess of procoagulant forces and/or a relative lack of anticoagulant forces can predispose […]

Comments (0)

Anticoagulant Therapy

Jul 13 2026

george

A LAC Assay that Resists DOAC Interference

Click Rahman M, Black KM, Sadeghi-Khomami A; An Automated Lupus Anticoagulant Assay Resistant to Anticoagulant Drugs Including DOACs and Oral FXI Inhibitors for a 2016 ISTH poster that documents an updated LAC assay. Background Direct oral anticoagulants (DOACs) and oral FXI inhibitors interfere with LAC testing by prolonging clotting times and increasing assay variability. Activated charcoal […]

Comments (0)

Anticoagulant Therapy

Jul 11 2026

george

Acquired von Willebrand Syndrome Review

Here is an open-access review of acquired von Willebrand syndrome from the December, 2025 Seminars in Thrombosis and Hemostasis issue devoted to VWD. Zetterberg E, Strandberg K, Hillarp A, et al. Acquired von Willebrand syndrome: a comprehensive review and a Nordic perspective. Semin Thromb Hemost. 2025. doi: 10.1055/a-2765-9556. PMID: 41429124. Abstract Acquired von Willebrand syndrome […]

Blog

External Quality Assessment for Anti-FXa LMWH Assays

Check with your local medical library for this thought-provoking article: Favaloro EJ, Arunachalam S, Pasalic L. External quality assessment for low molecular weight heparin monitoring in the Australasia/Asia-Pacific region. Semin Thromb Hemost. 2026. doi: 10.1055/a-2900-7026. Epub ahead of print. PMID: 42398957. Abstract LMWH remains a widely used parenteral anticoagulant in hospital and outpatient settings for […]

Comments (0)

Anticoagulant Therapy

Jul 6 2026

george

What is Anticoagulation Drift?

Click to read this LinkedIn post, where Edward Lee Carter, BSPharm, CPP, states: “The greatest threat to long-term anticoagulation may not be choosing the wrong drug. It may be failing to recognize that the patient has changed.” He illustrates the value of clinical laboratory assays to periodically confirm DOAC dosages.

Comments (0)

Anticoagulant Therapy

Jul 6 2026

george

Why Does Blood Group O Reduce VWF?

Dr. Abdul Mannan’s LinkedIn post, “Why Does Blood Group O Reduce VWF?” presents the physiology of VWF in blood group O.

Comments (0)

Bleeding Disorders

All Posts

August 2025 QQ: Coagulation Control Proteins

July 2026 QQ Summary: VWD Therapeutic

Emicizumab Therapy for the Newborn

Risk of PE in Octogenarians

Review: Laboratory Monitoring and Measuring of Clinical Anticoagulants

A LAC Assay that Resists DOAC Interference

Acquired von Willebrand Syndrome Review

External Quality Assessment for Anti-FXa LMWH Assays

What is Anticoagulation Drift?

Why Does Blood Group O Reduce VWF?

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question